Jefferies' high conviction US stocks for the summer: Nvidia among top picks

Jefferies highlighted its top 28 "highest-conviction Buy rated" US stocks, projecting significant upside based on differentiated analysis, catalysts, and valuation levels; these picks come after the S&P 500's 6.15% gain in May. Key selections include Nvidia, with a price target of $185 driven by the Blackwell ultra chips and margin improvement to mid-70%, DexCom, with a price target of $110 following approval for a new 15-day glucose monitoring sensor, and Capital One, with a price target of $230, citing synergies from the Discover Financial Services acquisition.

Analysis

Jefferies has issued a list of 28 "highest-conviction Buy rated" US stocks, timed as the US market experienced its best month in May since November 2023, with the S&P 500 gaining 6.15% after three prior months of decline. The brokerage asserts these selections are supported by differentiated analysis, specific catalysts, and attractive valuation levels. Key highlights include Nvidia (NVDA), with a $185 price target representing a 31% upside, predicated on the ramp-up of its Blackwell ultra chips and an anticipated margin expansion to the mid-70% range throughout the year; Nvidia shares are reported up 2% year-to-date. DexCom (DXCM) is another top pick with a $110 price target (27% upside), favored for its recent FDA approval of a 15-day glucose monitoring sensor and its strategy to expand into the Type 2 non-insulin patient market, both expected to drive significant margin improvement; DexCom stock has gained nearly 10% year-to-date. Capital One (COF) is recommended with a $230 target (18% upside), primarily due to the completed acquisition of Discover Financial Services, which is expected to unlock substantial network and operational synergies, alongside improving credit card trends poised to boost profitability; Capital One shares have risen over 8% year-to-date. The list also encompasses other stocks with varied year-to-date performances and significant projected upsides, such as DraftKings (DKNG) with a 74% upside despite a 5% year-to-date decline, and Argenx (ARGX) with a 33% upside despite a 6% year-to-date decline, suggesting Jefferies identifies specific value or recovery narratives.

Key Decisions for Investors

• Investors should consider Jefferies' high-conviction buy recommendations, particularly for Nvidia, DexCom, and Capital One, given the specific catalysts outlined such as new product cycles, market expansion, and synergistic M&A activity.
• It may be prudent to evaluate the underlying assumptions for the projected upsides, especially for stocks on the list that have experienced year-to-date declines, such as DraftKings or EPAM Systems, to align with individual risk tolerance and investment horizons.
• Monitor the identified catalysts for these selected companies, such as Nvidia's Blackwell chip adoption and Capital One's integration of Discover, as their realization will be key to achieving the forecasted price targets and justifying the bullish stance in the context of recent market strength.